Rating Change
Ladenburg Thalmann analysts initiated coverage on Editas Medicine, Inc. (NASDAQ:EDIT) with a rating of Buy on August 18, 2026.
new coverageNASDAQ:EDIT
Ladenburg Thalmann Initiates Coverage on Editas Medicine, Inc. (EDIT) with Buy
Ladenburg Thalmann analysts initiated coverage on Editas Medicine, Inc. (NASDAQ:EDIT) with a rating of Buy on August 18, 2026.
At publication ·
What changed
Editas Medicine, Inc. (NASDAQ:EDIT) · new coverage
- Firm
- Ladenburg Thalmann
- Rating
- Buy
- Price at event
- $2.88
- Market capitalization
- $217.7M
At a glance
Key takeaways
- Ladenburg Thalmann initiated Buy coverage on Editas Medicine (EDIT) on August 18, 2026, with the stock trading at $2.88 and a market capitalization of $217.7 million.
Market Context
Editas Medicine, Inc. operates in the Healthcare sector. The stock currently trades at $2.88 with a market capitalization of $217.7M.
Analyst coverage from Ladenburg Thalmann provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Editas Medicine, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Editas Medicine, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | Ladenburg Thalmann | Buy | N/A |
| May 05, 2026 | Chardan Capital | Buy | N/A |
| Mar 10, 2026 | Jones Trading | Buy | N/A |
| Mar 09, 2026 | Chardan Capital | Buy | N/A |
| Sep 05, 2025 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View EDIT Stock Page
Frequently Asked Questions
What does the Buy rating mean for EDIT?
A rating of Buy from Ladenburg Thalmann reflects the analyst's outlook on Editas Medicine, Inc. (NASDAQ:EDIT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the EDIT forecast page.